Matthew T. Wiley Bio Xcel Therapeutics, Inc. (BTAI) insider trading activity

Matthew T. Wiley is Chief Commercial Officer of BioXcel Therapeutics, Inc.. Currently has a direct ownership of 19,011 shares of BTAI, which is worth approximately $11,216. The most recent transaction as insider was on Oct 03, 2024, when has been sold 6,272 shares (Common Stock) at a price of $0.55 per share, resulting in proceeds of $3,449. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19K

443.48% 3M change

n/a 12M change

Total Value Held $11,216

Matthew T. Wiley Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 03 2024	SELL Open market or private sale	$3,449 $0.55 p/Share	6,272 Reduced 24.81%	19,011 Common Stock
Sep 17 2024	BUY Grant, award, or other acquisition	-	21,250 Added 45.67%	25,283 Common Stock
Sep 16 2024	SELL Open market or private sale	$148 $0.69 p/Share	215 Reduced 5.06%	4,033 Common Stock
Sep 15 2024	BUY Exercise of conversion of derivative security	-	750 Added 15.01%	4,248 Common Stock
Jun 17 2024	SELL Open market or private sale	$307 $1.26 p/Share	244 Reduced 6.52%	3,498 Common Stock
Jun 15 2024	BUY Exercise of conversion of derivative security	-	750 Added 16.7%	3,742 Common Stock
Apr 04 2024	SELL Open market or private sale	$2,661 $2.64 p/Share	1,008 Reduced 25.2%	2,992 Common Stock
Mar 15 2024	BUY Exercise of conversion of derivative security	-	3,000 Added 50.0%	3,000 Common Stock

Also insider at

VYNE

VYNE Therapeutics Inc. Healthcare

Chief Commercial Officer

MTW

Matthew T. Wiley

Chief Commercial Officer

Bridgewater, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BTAI shares.

Notify only if

Value

Insider Trading

Get notified when an Bio Xcel Therapeutics, Inc. insider buys or sells BTAI shares.

Notify only if

Operation

Value

Type

News

Receive news related to BioXcel Therapeutics, Inc.

Track Activities on BTAI

Account